The Globe and Mail reports in its Wednesday, Nov. 15, edition that Barclays analyst Benjamin Theurer has elevated his recommendation for Nutrien to "overweight" from "underweight." The Globe's David Leeder writes in the Eye On Equities column that Mr. Theurer gave his share target a $4 (U.S.) boost to $68 (U.S.). Analysts on average target the shares at $73.78 (U.S.). Mr. Theurer says in a note: "After a volatile third quarter and relative underperformance of K vs. N, we switch our recommendations and double-upgrade [Mosaic] and [Nutrien] to [overweight], given their K exposure, while upgrading ICL to [overweight] as well. We downgrade CF Industries to 'underweight' given recent relative outperformance." The Globe reported on July 7 that Credit Suisse analyst Edlain Rodriguez had reiterated his "underperform" call on Nutrien. The shares could be had for $60 (U.S.). The Globe reported on May 9 and Aug. 1 that TD Cowen analyst Michael Tupholme rated Nutrien at "hold" and "buy." It was then worth $64.50 (U.S.) and $67 (U.S.). The Globe reported on Nov. 3 that RBC Capital Markets analyst Andrew Wong continued to rate Nutrien "outperform." The shares could then be had for $56.22 (U.S.).